Bone Building Bisphosphonates Reduce Colon Cancer Risk

A new study shows that bisphosphonates such as Fosamax and Boniva may reduce patients’ risk of developing colon cancer. Women in particular tend to take these prescriptions after menopause and now have up to a 59% reduced risk of colon cancer development. Colon cancer affects men and women with equal frequency, but there is a common misperception that it’s a “man’s disease…

No Link Found Between Drugs Used To Treat Osteoporosis And Higher Risk Of Esophageal Cancer

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA…

Use Of Certain Drugs To Treat Osteoporosis Not Associated With Increased Risk Of Esophageal Or Gastric Cancer

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA…

Tip sheet for journalists: Equol, soy, menopause and bone health research published in Journal of Nutrition

( Porter Novelli ) The dietary supplement SE5-OH containing Natural S-equol, developed from soy, may be appropriate for women in menopause, based on results of recent clinical trials documenting its effectiveness and safety in relieving hot flushes and other symptoms of menopause. Nine articles on equol, soy, menopause, bone health and cancer research appear in a July 2010 supplement to the …

Lasofoxifene Helps Reduce Risk Of Bone Fractures, Breast Cancer, Heart Disease And Stroke

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That’s the finding of a new study in the latest issue of the New England Journal of Medicine…